The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)
Open accessAbstract
Background: There is limited data on antibiotic treatment in hospitalized neonates in low- and middle-income countries (LMICs). We aimed to describe patterns of antibiotic use, pathogens, and clinical outcomes, and to develop a severity score predicting mortality in neonatal sepsis to inform future clinical trial design. Methods and findings: Hospitalized infants <60 days with clinical sepsis were enrolled during 2018 to 2020 by 19 sites in 11 countries (mainly Asia and Africa). Prospective daily observational data was collected on clinical signs, supportive care, antibiotic treatment, microbiology, and 28-day mortality. Two prediction models were developed for (1) 28-day mortality from baseline variables (baseline NeoSep Severity Score); and (2) daily risk of death on IV antibiotics from daily updated assessments (NeoSep Recovery Score). Multivariable Cox regression models included a randomly selected 85% of infants, with 15% for validation. A total of 3,204 infants were enrolled, with median birth weight of 2,500 g (IQR 1,400 to 3,000) and postnatal age of 5 days (IQR 1 to 15). 206 different empiric antibiotic combinations were started in 3,141 infants, which were structured into 5 groups based on the World Health Organization (WHO) AWaRe classification. Approximately 25.9% (n = 814) of infants started WHO first line regimens (Group 1—Access) and 13.8% (n = 432) started WHO second-line cephalosporins (cefotaxime/ceftriaxone) (Group 2—“Low” Watch). The largest group (34.0%, n = 1,068) started a regimen providing partial extended-spectrum beta-lactamase (ESBL)/pseudomonal coverage (piperacillin-tazobactam, ceftazidime, or fluoroquinolone-based) (Group 3—“Medium” Watch), 18.0% (n = 566) started a carbapenem (Group 4—“High” Watch), and 1.8% (n = 57) a Reserve antibiotic (Group 5, largely colistin-based), and 728/2,880 (25.3%) of initial regimens in Groups 1 to 4 were escalated, mainly to carbapenems, usually for clinical deterioration (n = 480; 65.9%). A total of 564/3,195 infants (17.7%) were blood culture pathogen positive, of whom 62.9% (n = 355) had a gram-negative organism, predominantly Klebsiella pneumoniae (n = 132) or Acinetobacter spp. (n = 72). Both were commonly resistant to WHO-recommended regimens and to carbapenems in 43 (32.6%) and 50 (71.4%) of cases, respectively. MRSA accounted for 33 (61.1%) of 54 Staphylococcus aureus isolates. Overall, 350/3,204 infants died (11.3%; 95% CI 10.2% to 12.5%), 17.7% if blood cultures were positive for pathogens (95% CI 14.7% to 21.1%, n = 99/564). A baseline NeoSep Severity Score had a C-index of 0.76 (0.69 to 0.82) in the validation sample, with mortality of 1.6% (3/189; 95% CI: 0.5% to 4.6%), 11.0% (27/245; 7.7% to 15.6%), and 27.3% (12/44; 16.3% to 41.8%) in low (score 0 to 4), medium (5 to 8), and high (9 to 16) risk groups, respectively, with similar performance across subgroups. A related NeoSep Recovery Score had an area under the receiver operating curve for predicting death the next day between 0.8 and 0.9 over the first week. There was significant variation in outcomes between sites and external validation would strengthen score applicability. Conclusion: Antibiotic regimens used in neonatal sepsis commonly diverge from WHO guidelines, and trials of novel empiric regimens are urgently needed in the context of increasing antimicrobial resistance (AMR). The baseline NeoSep Severity Score identifies high mortality risk criteria for trial entry, while the NeoSep Recovery Score can help guide decisions on regimen change. NeoOBS data informed the NeoSep1 antibiotic trial (ISRCTN48721236), which aims to identify novel first- and second-line empiric antibiotic regimens for neonatal sepsis. Trial registration: ClinicalTrials.gov, (NCT03721302).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316 · cited 1×
“Antimicrobial resistance (AMR) increasingly threatens to undermine the effectiveness of antibiotics and potentially slow progress in reducing mortality, particularly in LMICs [4–10], with AMR-attributable neonatal deaths recently estimated between 140,000 [10] and 214,000 annually [11].”
BackgroundSelf-citationCorrespondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. (2015) · BMC Medicine · doi:10.1186/s12916-014-0241-z · Cited by 1,927
Okomo, U., Akpalu, E. N. K., Le Doare, K., Roca, A., Cousens, S., Jarde, A., Sharland, M., Kampmann, B., & Lawn, J. E. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30414-1 · Cited by 321
Self-citationNeonatal sepsis in South Asia: huge burden and spiralling antimicrobial resistance
Chaurasia, S., Sivanandan, S., Agarwal, R., Ellis, S., Sharland, M., & Sankar, M. J. (2019) · BMJ · doi:10.1136/bmj.k5314 · Cited by 258
Self-citationWynn, J. L., & Polin, R. A. (2020) · Pediatric Research · doi:10.1038/s41390-019-0517-2 · Cited by 169
Li, G., Bielicki, J. A., Ahmed, A. S. M. N. U., Islam, M. S., Berezin, E. N., Gallacci, C. B., Guinsburg, R., da Silva Figueiredo, C. E., Santarone Vieira, R., Silva, A. R., et al. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2019-316816 · Cited by 106 · cited 1×
“Sites were selected after conducting a feasibility study [18] to represent diverse regions and to include secondary and tertiary referral hospitals, public facilities, and facilities with varying proportions of in-born and out-born infants, with access to microbiology.”
MethodSelf-citationBortone, B., Jackson, C., Hsia, Y., Bielicki, J., Magrini, N., & Sharland, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0241899 · Cited by 54 · cited 1×
“Some countries are also using less widely used combinations such as cefoperazone/sulbactam, for which neonatal data are limited [29,30].”
Background
Cited by
The scope of the antimicrobial resistance challenge
Okeke, I. N., de Kraker, M. E. A., Van Boeckel, T. P., Kumar, C. K., Schmitt, H., Gales, A. C., Bertagnolio, S., Sharland, M., & Laxminarayan, R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00876-6 · Cited by 474
Self-citationAntimicrobial Resistance: Addressing a Global Threat to Humanity
Walsh, T. R., Gales, A. C., Laxminarayan, R., & Dodd, P. C. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004264 · Cited by 403
Williams, P. C. M., Jones, M., Snelling, T. L., Duguid, R., Moore, N., Dickson, B., Wu, Y., Saunders, J., Wijeratne, P., Douangnouvong, A., et al. (2024) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2023.100291 · Cited by 35
Metadata
- Authors
- Russell, N. J., Stöhr, W., Plakkal, N., Cook, A., Berkley, J. A., Adhisivam, B., Agarwal, R., Ahmed, N. U., Balasegaram, M., Ballot, D., Bekker, A., Berezin, E. N., Bilardi, D., Boonkasidecha, S., Carvalheiro, C. G., Chami, N., Chaurasia, S., Chiurchiu, S., Colas, V. R. F., Cousens, S., Cressey, T. R., de Assis, A. C. D., Dien, T. M., Ding, Y., Dung, N. T., Dong, H., Dramowski, A., DS, M., Dudeja, A., Feng, J., Glupczynski, Y., Goel, S., Goossens, H., Hao, D. T. H., Khan, M. I., Huertas, T. M., Islam, M. S., Jarovsky, D., Khavessian, N., Khorana, M., Kontou, A., Kostyanev, T., Laoyookhon, P., Lochindarat, S., Larsson, M., Luca, M. D., Malhotra-Kumar, S., Mondal, N., Mundhra, N., Musoke, P., Mussi-Pinhata, M. M., Nanavati, R., Nakwa, F., Nangia, S., Nankunda, J., Nardone, A., Nyaoke, B., Obiero, C. W., Owor, M., Ping, W., Preedisripipat, K., Qazi, S., Qi, L., Ramdin, T., Riddell, A., Romani, L., Roysuwan, P., Saggers, R., Roilides, E., Saha, S. K., Sarafidis, K., Tusubira, V., Thomas, R., Velaphi, S., Vilken, T., Wang, X., Wang, Y., Yang, Y., Zunjie, L., Ellis, S., Bielicki, J. A., Walker, A. S., Heath, P. T., & Sharland, M.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2023-06-08
- Volume
- 20
- Issue
- 6
- Pages
- e1004179
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W4379966434
- Cited by
- 184
- References
- 9
- FWCI
- 42.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.